BioSpace News Archive

Pluristem Therapeutics Inc. today announced topline results from its Phase II dose escalation studies evaluating the safety and efficacy of intramuscular injections of PLX-PAD cells for the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19.

Mentice and Siemens Healthineers China announce that Mentice VIST ® Virtual Patient simulators will be included with the sale of every Corindus CorPath GRX Robotic system (CorPath GRX) in China on an initial 3-year agreement, starting 2022.

Grand Pharma has licensed the development, manufacturing and commercialization rights of ITM’s Targeted Radionuclide Therapeutic candidates ITM-11 (n.c.a 177 Lu-edotreotide) and ITM-41 (n.c.a 177 Lu-zoledronate) as well as diagnostic TOCscan® ( 68 Ga-edotreotide) for the treatment and diagnosis of cancer patients in Greater China

BiondVax Pharmaceuticals Ltd. today announced the pricing of an underwritten public offering of 3,813,560 American Depositary Shares.

Gross proceeds made available to Pardes Biosciences from transaction totaled approximately $274 million, combining approximately $199 million of funds held in FS Development Corp.

BrainStorm Cell Therapeutics Inc. today announced plans for a dosing extension of NurOwn® for participants who completed the Expanded Access Protocol (EAP).

Revolo Biotherapeutics today announced the appointment of industry veteran Tunde Otulana, M.D., to its Board of Directors.

PharmAbcine Inc. today announced it has dosed the first patient in its Phase II clinical trial evaluating the combination of olinvacimab, PharmAbcine’s anti-VEGFR2.

Faraday Pharmaceuticals, Inc. announced today the publication of results from its Phase 2 trial of FDY-5301 for the treatment of reperfusion injury following an ST-elevation myocardial infarction (STEMI) in the January 15, 2022 issue of the International Journal of Cardiology.

Castellum, Inc. (OTC: ONOV) announces the signing of a letter-of-intent (LOI) to acquire an East-coast based government contractor generating over $4 million in annualized revenue.